Berko Pharmaceuticals, a strong brand in the Turkish pharmaceutical market and a pioneer in achieving "For Healthy Tomorrows", has taken another important step towards becoming a global brand and has signed a cooperation agreement with Dong-A ST and Orphamed Pharma at CPHI Worldwide 2023.
Berko Pharmaceuticals signed an important collaboration at CPHI Worldwide 2023, which it visited after obtaining EU GMP certification. Berko Pharmaceuticals, which signed a cooperation agreement with Dong-A ST and Orphamed Pharma for products and fixed dose combinations indicated in the treatment of Type II Diabetes, continues to make a name for itself with its projects.
As one of the strategic breakthroughs of Berko Pharmaceuticals, it is aimed to transfer technology to Berko Pharmaceuticals Manufacturing Facility in cooperation with the originator company for products in the original product category indicated in the treatment of Type II Diabetes for the treatment of chronic diseases and to offer the finished product to the service of Turkish medicine.
Regarding the issue, Berko Pharmaceuticals General Manager Pharm Barış Özyurtlu said that “At CPHI Worldwide 2023, which we visited after obtaining the EU GMP certificate, we came together with our stakeholders in the healthcare sector and held important meetings. I believe that we have taken another important step towards increasing our competitiveness in the global market and becoming a world brand. I wish this strategically important cooperation will be beneficial for our healthcare sector.”